Royalty Pharma plc (RPRX) has acquired a royalty interest in Amgen's Imdelltra, a DLL3 targeting bispecific T-cell engager, from BeOne Medicines for $885 million upfront. The agreement includes an option for BeOne to sell additional Imdelltra royalties to Royalty Pharma for up to $65 million. BeOne will retain China commercial rights to Imdelltra.
Imdelltra received accelerated approval from the FDA in May 2024 for the treatment of extensive-stage small cell lung cancer in patients who have progressed on or after receiving platinum-based chemotherapy. Amgen is currently enrolling Phase 3 studies for Imdelltra in front-line small cell lung cancer.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.